Lifecore Biomedical/Iolab
This article was originally published in The Gray Sheet
Executive Summary
Sign letter of understanding whereby Lifecore would supply the Johnson & Johnson subsidiary with ophthalmic sodium hyaluronate for its Amvisc and Amvisc Plus viscoelastic solutions through Dec. 31, 2000. Under the agreement, expected to be finalized in a month to six weeks, Lifecore will manufacture raw material powder and finished sterile-filled syringe forms of the two products, the firm explains. Iolab "would be granted exclusive rights to certain molecular weight ranges of Lifecore's hyaluronate for use in ophthalmic viscoelastic solutions" that are not expected to be in full commercialization until 1997. Lifecore and Iolab already have a research and development agreement relating to high molecular weight hyaluronate